CORMEDIX THERAPEUTICS TO REPORT THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 12, 2026

November 6, 2026

Parsippany, NJ – November 6, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.

Thursday, November 12^th at 8:30 a.m. EST
Domestic:                       1-844-676-2922
International:                1-412-634-6840
Webcast:                         Webcast Link
 

About CorMedix

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field-based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576